Press Releases

AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that new data from its ongoing, collaborator-sponsored 1 Phase 1/2 clinical trial

May 03, 2022

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 6, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to

Apr 06, 2022

AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 5, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Geoff MacKay , president and CEO of AVROBIO , will present at the 21 st Annual

Apr 05, 2022

AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

Provided interim data at WORLDSymposium™   2022 that showed sustained engraftment across first three patients 1 + year post-gene therapy in Phase 1/2 clinical trial i for cystinosis; all remain off oral cysteamine to date Interim clinical data update of AVR-RD-02 in Gaucher disease type 1 planned

Mar 17, 2022

AVROBIO to Present at Two Upcoming Investor Conferences in March

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 1, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two

Mar 01, 2022

AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Sustained engraftment observed across first three patients 1+ year post-gene therapy; all remain off oral cysteamine to date Reduction in number of cystine crystals as measured in skin and intestinal mucosa biopsies observed across first three patients Continued favorable safety profile with no

Feb 09, 2022

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 4, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to

Feb 04, 2022

AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 1, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced the appointment of Sean O’Bryan as chief regulatory officer.

Feb 01, 2022

AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 28, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO , will present

Jan 28, 2022

AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022

Analyst and investor conference call scheduled for Wednesday, Feb. 9, 2022 , at 8:00 a.m. ET Five platform presentations and three posters on the company’s clinical and preclinical programs for lysosomal disorders are scheduled throughout the symposium CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan.

Jan 27, 2022



Displaying 11 - 20 of 22

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.